Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  sunitinib malate
Find trials that include:  Any drugs shown
Results 1-22 of 22 for your search:
Start Over
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991003, NCI-2016-00392, 2015-002429-20, JAVELIN RENAL 101, NCT02684006
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-426, NCI-2016-01738, 163460, 2016-000588-17, NCT02853331
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: E7080-G000-307, NCI-2017-00073, NCT02811861
Savolitinib vs. Sunitinib in MET-driven PRCC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D5082C00003, NCI-2017-01000, NCT03091192
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Sunitinib Malate or Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 20
Trial IDs: 8875, NCI-2013-01496, 110200, 11-C-0200, P11836, NCT01391962
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 21
Trial IDs: A6181196, NCI-2014-00205, 2011-002008-33, NCT01396148
Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: IRB00007195, NCI-2012-01084, CA180-392, NCT01620216
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13P.377, NCI-2014-00338, 2013-047, NCT02068586
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 150040, 339636, P141605, NCT02315625
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IM-201, NCI-2017-01271, 2014-004510-28, NCT02432846
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients with Locally Advanced or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: S1500, NCI-2015-01707, NCT02761057
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00014171, NCI-2017-00510, NCT02693535
Alternative Schedule Sunitinib Malate in Treating Patients with Advanced or Metastatic Kidney Cancer or That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00072588, NCI-2017-01131, NCT03109015
Sunitinib Malate Alternating with Regorafenib in Treating Patients with Gastrointestinal Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-149, NCI-2014-02033, ONC-2013-024, WI186553, NCT02164240
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B7791001, NCI-2016-00393, PRCA VBIR FIP STUDY, NCT02616185
Personalized Kinase Inhibitor Therapy Combined with Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 64
Trial IDs: IRB00011766, NCI-2016-00083, NCT02779283
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: A6181036, NCI-2010-01834, NCT00094029
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: A6181037, NCI-2013-01674, NCT00130897
Collection of Tumor Samples in Identifying Potential Predictors of Response to Novel Therapies in Patients with Metastatic Pancreatic Neuroendocrine Tumors
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 12-058, NCI-2016-01730, NCT01603004
Start Over